Skip to main content
David Snyder, MD, Hematology, Duarte, CA

DavidSnyderMD

Hematology Duarte, CA

Physician

Dr. Snyder is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

  • Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
  • Connect with colleagues in the same hospital or clinic.
  • Read the latest clinical news, personalized to your specialty.

See Dr. Snyder's full profile

Already have an account?

  • Office

    1500 Duarte Rd
    Duarte, CA 91010
    Phone+1 626-359-8111
    Fax+1 626-218-5310

Education & Training

  • Tufts Medical Center
    Tufts Medical CenterFellowship, Hematology and Medical Oncology, 1982 - 1984
  • Beth Israel Deaconess Medical Center
    Beth Israel Deaconess Medical CenterResidency, Internal Medicine, 1978 - 1980
  • New York Presbyterian Hospital (Columbia Campus)
    New York Presbyterian Hospital (Columbia Campus)Internship, Internal Medicine, 1977 - 1978
  • Harvard Medical School
    Harvard Medical SchoolClass of 1977

Certifications & Licensure

  • CA State Medical License
    CA State Medical License 1984 - 2025
  • American Board of Internal Medicine Internal Medicine
  • American Board of Internal Medicine Hematology

Clinical Trials

Publications & Presentations

PubMed

Abstracts/Posters

  • Optimization of Tacrolimus Serum Levels When Combined with Post-Transplant Cyclophosphamide As Graft-Versus-Host Disease Prophylaxis after Hematopoietic Cell Transplan...
    David Snyder, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
  • Spred1 Insufficiency in the Hematopoietic and/or Vascular Compartments of the Bone Marrow (BM) Niche Promotes Aggressive Leukemogenesis in Chronic Myelogenous Leukemia...
    David Snyder, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
  • Peri-Transplant Administration of Ruxolitinib Is Safe and Feasible in Patients with Myelofibrosis: Primary Results of a Pilot Open-Label Study of Ruxolitinib Administr...
    David Snyder, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019

Lectures

  • MIPSS70+ V2.0 and Revised Cytogenetics Changes Predict Outcomes of Allogeneic Transplantation with Fludarabine and Melphalan Conditioning in Patients with Myelofibrosis 
    2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
  • Clinical Outcomes of MDS Patients Who Were Allogeneic Hematopoietic Stem Cell Transplant Candidates but Did Not Proceed with Transplantation 
    2018 ASH Annual Meeting - San Diego, CA - 12/1/2018

Press Mentions

  • 2 City of Hope Physicians Recognized for Compassionate Patient Care, Innovative Leadership
    2 City of Hope Physicians Recognized for Compassionate Patient Care, Innovative LeadershipDecember 8th, 2020
  • Imetelstat Promising Across Myeloproliferative Neoplasms
    Imetelstat Promising Across Myeloproliferative NeoplasmsSeptember 4th, 2015